Author: CAPD

Conservatives Agree: Restricting Pharmacy Benefits Will Harm Patients, Taxpayers

GOP candidates will soon take the stage for one of the biggest political moments of the year: the…

Big Pharma is Playing a Dangerous Game with GLP-1s

It’s hard to miss the recent headlines about new weight-loss drugs like Ozempic and Wegovy. Called GLP-1s, these…

How Big Pharma’s Product Hops Hurt HIV/AIDS Care

Over the last twenty years, new medications have dramatically changed the fight against HIV/AIDS. These medications – called…

Big Pharma really doesn’t mind if the government picks winners and losers – so long as it is always the winner.

We took note of two recent POLITICO articles that make very, very clear the reality of what’s going…

Partial Transparency is No Transparency at All

Although Congress has devoted much attention to exploring pharmaceutical manufacturers and pharmacy benefit managers, less attention has been…

Conservative Voices: Beware the Rush to Regulate

As Congress continues to examine the drug supply chain and how to lower prescription drug prices for Americans,…

Reason: Patient Privacy at Risk in S. 127

As Congress returns for a new work period, both parties are renewing their focus on how to bring…

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition

Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat…

Guest Opinion: Taking Action on the Price of Prescription Drugs: A Winning Formula

By: Ed Goeas and Brian Nienaber Read the original post on LinkedIn here. Ahead of the upcoming mid-term…

House Advances CAPD-Supported Measures to Lower Drug Prices for Patients

Americans have overwhelmingly supported action by Congress to lower Big Pharma’s drug prices for years, and now –…